These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29949609)

  • 21. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection for EGFR gene amplification in a breast epithelial cell line with basal-like phenotype and hereditary background.
    Ingthorsson S; Halldorsson T; Sigurdsson V; Friðriksdottir AJ; Bodvarsdottir SK; Steinarsdottir M; Johannsson O; Magnusson MK; Ogmundsdottir HM; Gudjonsson T
    In Vitro Cell Dev Biol Anim; 2011 Feb; 47(2):139-48. PubMed ID: 21082277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
    Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
    Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
    Reyes C; Jorda M; Gomez-Fernández C
    Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteolysis-a characteristic of tumor-initiating cells in murine metastatic breast cancer.
    Hillebrand LE; Bengsch F; Hochrein J; Hülsdünker J; Bender J; Follo M; Busch H; Boerries M; Reinheckel T
    Oncotarget; 2016 Sep; 7(36):58244-58260. PubMed ID: 27542270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of CD90 (Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment.
    Zhu J; Thakolwiboon S; Liu X; Zhang M; Lubman DM
    PLoS One; 2014; 9(12):e115507. PubMed ID: 25536077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
    Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
    Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
    Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study.
    Zhang L; Liu Z; Zhu J
    Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
    BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deconstructing the molecular portrait of basal-like breast cancer.
    Yehiely F; Moyano JV; Evans JR; Nielsen TO; Cryns VL
    Trends Mol Med; 2006 Nov; 12(11):537-44. PubMed ID: 17011236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
    Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
    Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
    Fadare O; Tavassoli FA
    Adv Anat Pathol; 2007 Sep; 14(5):358-73. PubMed ID: 17717437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.
    Ma J; Liu C; Yang D; Song J; Zhang J; Wang T; Wang M; Xu W; Li X; Ding S; Zhan J; Zhang H
    Sci China Life Sci; 2019 Sep; 62(9):1229-1242. PubMed ID: 31376015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
    Holcakova J; Nekulova M; Orzol P; Nenutil R; Podhorec J; Svoboda M; Dvorakova P; Pjechova M; Hernychova L; Vojtesek B; Coates PJ
    Breast Cancer Res Treat; 2017 Jun; 163(3):475-484. PubMed ID: 28349272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.